SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as community members discuss the potential impact of AI-assisted biopsy qualification on their MASH program and upcoming 48-week data, speculating on accelerated approval pathways. Bullish investors are expressing confidence in the science, with community chatter focusing on a possible buyout and significant upside potential in the MASH and obesity treatment space. The focus is on the company's potential as a leader in its sector.

AlphaTime Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on September 15, 2021 and is headquartered in New York, NY.

AlphaTime Acquisition Corp

AlphaTime Acquisition Corp ($ATMC) is trending after shareholder approval of its merger with HCYC, a Hong Kong-based insurance brokerage, triggering a massive after-hours surge. The community is discussing the low float, potential for a short squeeze, and comparing it to similar plays like $SMX, with some speculating on targets, while others caution about the risks of chasing low-float stocks.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet's price is trending as community members highlight recent staking milestones and the potential for Bitcoin DeFi (BTCFi) integration on the layer-2 network. The integration of Bitcoin staking into Starknet's consensus is a key discussion point, alongside its quantum-resistant technology. Some users also suggest Starknet is primed for a breakout, drawing comparisons to Solana's earlier growth.

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

XCUR is trending due to positive Phase 2 data for its multiple myeloma treatment, driving significant after-hours volume. The community is focused on the stock's low float and potential for a short squeeze, while some traders caution about chasing the rally. Links to the news and potential catalysts are being shared.

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Vor Biopharma Inc

VOR is trending due to JP Morgan's recent Overweight rating and a $43 price target, sparking community discussion around the large discrepancy between the target and a previous offering price.  The stock is also experiencing increased momentum and high trading volume, leading to speculation about a potential short squeeze and further price appreciation. Community members are actively debating the merits of the stock and watching for potential entry and exit points.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision of being a culture coin on the Solana blockchain. Advocates highlight its focus on community, real-world presence, and connection to cannabis culture. The project aims to foster organic growth within the web3 space, emphasizing a long-term vision.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is trending amid community excitement surrounding upcoming catalysts and potential government support in the rare earths sector. Bullish sentiment is fueled by speculation around the BFS report and potential EU-backed deals, with some traders eyeing a return to previous highs. Discussions also involve the company's financials and the strategic importance of rare earth elements.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is trending amid speculation of a hostile takeover bid for Warner Bros. Discovery (WBD), potentially outbidding Netflix; the community is actively discussing the likelihood of regulatory approval, potential financial implications, and which company offers the best deal for WBD shareholders. Community members are weighing the impact of a potential merger with WBD against the company's prospects as a standalone entity.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is trending due to positive interim results from its obesity drug trial, showing fat loss and muscle preservation, a potential advantage over existing treatments. Community discussions focus on the drug's promise and analysts' upgraded ratings, while some traders are eyeing potential short squeeze setups amid high volatility and upcoming data releases. The broader context includes increased interest in obesity drugs and potential M&A activity in the pharmaceutical sector.

AlphaVest Acquisition Corp. is a blank check company, which engages in effecting a merger, stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded on January 14, 2022 and is headquartered in New York, NY.

AlphaVest Acquisition Corp

ATMV is trending due to discussions around a potential merger, reminiscent of other SPACs that have seen significant volatility. Community chatter highlights the stock's low float and high borrow fees, leading to speculation about potential short squeezes and comparisons to similar runners. The stock has experienced significant price swings and trading volume, prompting both bullish and bearish sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>All eyes are on the Fed’s rate decision scheduled for Wednesday.&nbsp;</li><li>NVIDIA is in the spotlight after President Donald Trump declared on Monday that the U.S. will allow it to ship its H200 chips to China and other countries upon fulfillment of certain conditions, even as reports emerge of Beijing limiting access.</li><li>Retail sentiment on Stocktwits for the S&amp;P 500 ETF and Invesco QQQ was in the ‘bearish’ territory.</li></ul>U.S. equities are treading cautiously in Tuesday’s premarket session as investors await the Fed’s key rate policy decision due on Wednesday.While Dow Jones futures were up by 0.11% at the time of writing, the S&amp;P 500 futures rose 0.04% while the Nasdaq 100 futures declined 0.03%.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) was up by 0.06%,&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ) edged 0.03% lower, and&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) rose 0.11% in premarket. Retail sentiment around the S&amp;P 500 ETF and Invesco QQQ on Stocktwits was in the ‘bearish’ territory.<h2 class="st-heading-2">Fed Rate Anticipation</h2>While the market expects a 25-basis-point cut, uncertainty about fresh tariffs on Mexico, Canada, and India is also affecting investor sentiment.&nbsp;There is an 89.4% probability of a 25 basis point rate cut this week, according to the latest data from the&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">CME FedWatch</a> tool. Last week, Morgan Stanley joined peers JPMorgan and Bank of America (BofA) to revise its expectations and reiterate a 25-basis-point cut from its previous expectation of a status quo policy.<h2 class="st-heading-2">Stocks To Watch</h2>Nvidia (NVDA): The chip giant is in the spotlight after President Donald Trump declared on Monday that the U.S. will allow it to ship its H200 chips to China and other countries upon fulfillment of certain conditions, even as reports emerge of Beijing limiting access. Shares of&nbsp;<a href="https://stocktwits.com/symbol/NVDA">NVDA</a> are up 1.7% in premarket trading.Vor Biopharma (VOR):&nbsp;<a href="https://stocktwits.com/symbol/VOR">VOR shares</a> are up over 26% at the time of writing due to positive sentiment around a recent Phase 3 clinical study. JPMorgan has initiated coverage on Vor Bio with a bullish view.Exicure Inc (XCUR): The early-stage biotech company&nbsp;<a href="https://stocktwits.com/symbol/XCUR">XCUR</a> is up over 77% in premarket trading because of positive Phase 2 trial results for its cancer treatment.GameStop (GME), Dave &amp; Buster's (PLAY), Core &amp; Main Inc (CNM), SailPoint Technologies (SAIL), and Casey's General Stores (CASY) are among the companies scheduled to report their latest quarterly earnings on Tuesday.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The New York Stock Exchange (NYSE) stands off Wall Street on April 17, 2025 in New York City. (Photo by Spencer Platt/Getty Images)

Futures Tread Cautiously Pre-Market As Investors Await Key Fed Decision: NVDA, XCUR, GME, CASY Among Stocks To Watch

The Dow Jones futures were up by 0.11% while the S&P 500 futures were up 0.04%. 

Equity

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Hold" from Brokerages

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has been given a consensus rating of "Hold" by the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. One...

Wedbush Predicts Vor Biopharma's Q4 Earnings (NASDAQ:VOR)

Vor Biopharma Inc. (NASDAQ:VOR - Free Report) - Research analysts at Wedbush issued their Q4 2025 EPS estimates for shares of Vor Biopharma in a research note issued to investors on Tuesday, November...

Wedbush Initiates Coverage on Vor Biopharma (NASDAQ:VOR)

Wedbush restated a "neutral" rating and issued a $9.00 price target on shares of Vor Biopharma in a research note on Tuesday...

Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know

Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Vor Biopharma (NASDAQ:VOR) Posts Quarterly Earnings Results, Misses Expectations By $0.27 EPS

Vor Biopharma (NASDAQ:VOR - Get Free Report) announced its earnings results on Thursday. The company reported ($3.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates...

Vor Biopharma (NASDAQ:VOR) Price Target Cut to $32.00 by Analysts at HC Wainwright

HC Wainwright decreased their price target on Vor Biopharma from $55.00 to $32.00 and set a "buy" rating for the company in a research note on Friday...

Zacks Research Upgrades Vor Biopharma (NASDAQ:VOR) to "Hold"

Zacks Research raised shares of Vor Biopharma from a "strong sell" rating to a "hold" rating in a research report on Tuesday...

Investors Buy High Volume of Vor Biopharma Put Options (NASDAQ:VOR)

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 8,702 put options on the company. This represents an increase of...

Vor Biopharma Prices Public Offering Of 10 Mln Shares At $10.00/shr

(RTTNews) - Vor Biopharma Inc. (VOR) announced the pricing of an underwritten public offering of 10 million shares of its common stock at a public offering price of $10.00 per share...

VOR
Vor Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VOR News

VORVor Biopharma Inc